Evaxion A/S (NASDAQ:EVAX) Price Target Cut to $9.00 by Analysts at Lake Street Capital

Evaxion A/S (NASDAQ:EVAX) had its price objective reduced by Lake Street Capital from $11.00 to $9.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Maxim Group assumed coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

Evaxion A/S Price Performance

Shares of EVAX opened at $3.08 on Monday. Evaxion A/S has a twelve month low of $1.20 and a twelve month high of $12.15. The company has a market capitalization of $25.69 million, a P/E ratio of -2.33 and a beta of 0.28. The firm has a 50 day moving average of $3.87 and a 200 day moving average of $4.63. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings data on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. As a group, equities research analysts anticipate that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of EVAX. SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S during the 4th quarter valued at $72,000. Wesbanco Bank Inc. purchased a new position in Evaxion A/S during the fourth quarter valued at $48,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S during the fourth quarter valued at about $38,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.